Esco seeks to incubate, acquire biotech firms in China as part of global ecosystem strategy
Xiang Qian (XQ) Lin, CEO of Esco Group Premium
Armed with $200 million funding led by Vivo Capital and Novo Holdings last month, Singapore’s Esco Lifesciences is looking at an accelerated expansion in China, creation of an innovation hub in Boston, acquisition of Western technologies and bringing them to the Asian market, as well as pursuing an active M&A strategy.
“We are building a global life sciences ecosystem between Singapore, the US and China, with Singapore as the focal nexus,” Esco CEO Lin Xiangqian said in a video interview with DealStreetAsia from Shanghai.
Moderna enlisted Samsung Biologics to help with fill-finish of its mRNA COVID-19 vaccine. Astellas targeted $17 billion in fiscal 2025 sales in a new five-year plan. Novo Holdings co-led a $200 million financing round in a Singapore cell and gene therapy tech company. And more
Esco Lifesciences ("Esco", the "Company") announced today the close of an over-subscribed US$200 million Series A and Crossover round. The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation, Singapore-based global investor EDBI, a reputable, long-term institutional investor, and other sophisticated investors.
- Largest private financing round by an Asia-based life sciences tools company - Important milestone in the development of Novo Holdings' ambitions in Asia - As a result of the financing